U.S. pharma large copyright scrapped two experimental weight loss products previous yr—a once-everyday pill, lotiglipron, as a consequence of elevated liver enzymes and a 2 times-each day capsule, danuglipron, as a result of robust side effects—but CEO Albert Bourla has claimed the c